Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Top Cited Papers
- 1 May 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 3 (5), 269-280
- https://doi.org/10.1038/ncponc0509
Abstract
Nature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 84 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancerBritish Journal of Surgery, 2002
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Identification of a Novel Mitogen-Inducible Gene (mig-6): Regulation during G1 Progression and DifferentiationExperimental Cell Research, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987